Name
Põltsamaa Uus Apteek OÜ
Registry code
10034945
VAT number
EE100661572
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
29.05.1996 (28)
Financial year
01.01-31.12
Capital
2 556.00 €
Activity
47731 - Dispensing chemist in specialised stores
1 919 758 €
68 666 €
4%
1 755 €
(estimate is approximate)
117 246 €
7
Submitted
No tax arrears
59%
20%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Ülle Rebane 04.07.1963 (61) | 100% - 2 556.00 EUR | Board member (chairman) | Direct ownership |
| 2019 04.06.2020 | 2020 28.06.2021 | 2021 21.06.2022 | 2022 30.06.2023 | 2023 10.05.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 1 726 064 € | 1 813 557 € | 1 867 707 € | 1 853 146 € | 1 919 758 € |
| Net profit (loss) for the period | 88 833 € | 77 507 € | 97 056 € | 89 320 € | 68 666 € |
| Profit Margin | 5% | 4% | 5% | 5% | 4% |
| Current Assets | 308 258 € | 346 365 € | 335 511 € | 350 062 € | 341 492 € |
| Fixed Assets | 313 334 € | 287 042 € | 14 049 € | 3 591 € | 858 € |
| Total Assets | 621 592 € | 633 407 € | 349 560 € | 353 653 € | 342 350 € |
| Current Liabilities | 166 313 € | 186 573 € | 229 041 € | 225 073 € | 225 104 € |
| Non Current Liabilities | 11 120 € | 6 237 € | 1 259 € | 0 € | - |
| Total Liabilities | 177 433 € | 192 810 € | 230 300 € | - | - |
| Share Capital | - | - | - | - | - |
| Equity | 444 159 € | 440 597 € | 119 260 € | 128 580 € | 117 246 € |
| Employees | 8 | 9 | 9 | 7 | 7 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 509 954.18 € | 29 201.55 € | 20 060.23 € | 6 |
| 2023 Q4 | 489 570.1 € | 31 044.33 € | 20 418.91 € | 6 |
| 2023 Q3 | 480 858.85 € | 30 261.17 € | 21 775.33 € | 6 |
| 2023 Q2 | 477 810.9 € | 30 259.74 € | 20 040.24 € | 6 |
| 2023 Q1 | 482 305.34 € | 29 350.97 € | 19 749.65 € | 6 |
| 2022 Q4 | 488 618.02 € | 29 991.29 € | 20 785.15 € | 6 |
| 2022 Q3 | 454 537.84 € | 28 992.74 € | 20 146.55 € | 7 |
| 2022 Q2 | 445 228.71 € | 30 924.17 € | 20 189.21 € | 7 |
| 2022 Q1 | 449 272.15 € | 30 316.26 € | 19 614.12 € | 7 |
| 2021 Q4 | 505 712.09 € | 39 473.29 € | 24 018.98 € | 7 |
| 2021 Q3 | 472 389.8 € | 37 314.02 € | 24 881.14 € | 9 |
| 2021 Q2 | 461 127.36 € | 38 086.13 € | 24 372.46 € | 9 |
| 2021 Q1 | 444 495.01 € | 40 229.07 € | 23 196.49 € | 10 |
| 2020 Q4 | 463 997.3 € | 33 207.58 € | 22 216.07 € | 10 |
| 2020 Q3 | 440 808.17 € | 37 250.21 € | 22 641.84 € | 10 |
| 2020 Q2 | 467 240.63 € | 35 956.17 € | 20 202.87 € | 10 |
| 2020 Q1 | 450 954.75 € | 38 029.87 € | 23 678.1 € | 9 |
